Phaseline

Targets › MUC1

MUC1 (Mucin-1): drug programs, companies and trials

10 programs from 7 companies in 17 trials: 14 Phase 1, 3 Phase 2; Oncology; next expected readout Dec 2026.

The alpha subunit has cell adhesive properties. Can act both as an adhesion and an anti-adhesion protein. (UniProt, P15941)

Open in Phaseline: the race on MUC1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
National Cancer Institute (NCI)MUC1 Peptide-Poly-ICLC Vaccine
MUC1 peptide vaccine with poly-ICLC adjuvant for immunotherapy
MUC1Phase 2Colorectal Adenoma; Lung CarcinomaDec 2026
National Cancer Institute (NCI)Adenovirus 5 CEA/MUC1/Brachyury Vaccine Tri-Ad5
Therapeutic cancer vaccine expressing CEA, MUC1, and Brachyury tumor-associated antigens
CEA, MUC1, TBXTPhase 2Colorectal CarcinomaJul 2027
National Cancer Institute (NCI)Therapeutic CEA, Brachyury and MUC1 TriAdeno Vaccine Platform
Adenoviral-based cancer vaccine targeting CEA, Brachyury and MUC1
CEA, BRACHYURY, MUC1, KLK3, TBXTPhase 2Adenocarcinoma; Metastatic Colorectal CancerOct 2027
Beijing BiotechEB-DNK101 dual-targeting CAR-NK cells (MSLN + MUC1)
Allogeneic CAR-NK cells with dual-recognition CAR targeting MSLN and MUC1
MSLN, MUC1Phase 1Pancreatic Ductal Adenocarcinoma (PDAC)Feb 2027
National Cancer Institute (NCI)Falimarev (Fowlpox-CEA-MUC-1-TRICOM)
Recombinant fowlpox virus expressing CEA and MUC-1 tumor-associated antigens with TRICOM c
CEA, MUC1Phase 1Locally Advanced Pancreatic AdenocarcinomaApr 2027
Finn, Olivera, PhDMUC1 Peptide Vaccine
Therapeutic vaccine targeting MUC1, a transmembrane glycoprotein in the mucin family, for
MUC1Phase 1Ductal Carcinoma in SituFeb 2028
Olivera FinnMUC1 100mer peptide vaccine
MUC1 peptide vaccine with PolyICLC adjuvant
MUC1Phase 1Non-small Cell Lung Cancer (NSCLC)Oct 2028
NEOK BioNEOK002
EGFR and MUC1-targeting bispecific antibody-drug conjugate (ADC)
EGFR, MUC1Phase 1Locally Advanced (Unresectable) or Metastatic Solid TumorsFeb 2029
Minerva BiotechnologieshuMNC2-CAR44 CAR T cells
Anti-MUC1* (cleaved MUC1) CAR T cell therapy
MUC1Phase 1Metastatic Breast CancerJan 2035
Poseida TherapeuticsP-MUC1C-ALLO1
Allogeneic CAR-T cell therapy targeting MUC1-C
MUC1Phase 1Breast CancerApr 2039

Conditions

Pancreatic Ductal Adenocarcinoma (PDAC) (4) Locally Advanced Pancreatic Adenocarcinoma (2) Metastatic Breast Cancer (2) Adenocarcinoma (1) Metastatic Colorectal Cancer (1) Ductal Carcinoma in Situ (1) Breast Cancer (1) Locally Advanced (Unresectable) or Metastatic Solid Tumors (1) Colorectal Adenoma (1) Lung Carcinoma (1) Non-small Cell Lung Cancer (NSCLC) (1) Colorectal Carcinoma (1)

Modalities

mixed (5), other (3), protein or peptide (1), small molecule (1)

Companies

National Cancer Institute (NCI) (4) Finn, Olivera, PhD (1) Minerva Biotechnologies (1) Poseida Therapeutics (1) Beijing Biotech (1) NEOK Bio (1) Olivera Finn (1)

Related targets

CEA (3) TBXT (2) BRACHYURY (1) KLK3 (1) MSLN (1) EGFR (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.